Market Cap
US$3.9b
Last Updated
2020/10/21 00:14 UTC
Data Sources
Company Financials +
Executive Summary
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Insmed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INSM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
8.8%
INSM
-3.0%
US Biotechs
-1.3%
US Market
1 Year Return
111.4%
INSM
33.9%
US Biotechs
18.5%
US Market
Return vs Industry: INSM exceeded the US Biotechs industry which returned 33.9% over the past year.
Return vs Market: INSM exceeded the US Market which returned 18.5% over the past year.
Shareholder returns
| INSM | Industry | Market | |
|---|---|---|---|
| 7 Day | 8.8% | -3.0% | -1.3% |
| 30 Day | 18.0% | 1.8% | 5.3% |
| 90 Day | 47.6% | -3.7% | 7.5% |
| 1 Year | 111.4%111.4% | 36.2%33.9% | 21.3%18.5% |
| 3 Year | 45.7%45.7% | 19.1%13.1% | 42.4%32.9% |
| 5 Year | 86.0%86.0% | 15.2%7.0% | 84.2%63.5% |
Price Volatility Vs. Market
How volatile is Insmed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Should Investors React To Insmed's (NASDAQ:INSM) CEO Pay?1 month ago | Simply Wall St
Have Insiders Sold Insmed Incorporated (NASDAQ:INSM) Shares Recently?1 month ago | Simply Wall St
The Insmed (NASDAQ:INSM) Share Price Is Up 58% And Shareholders Are Holding OnValuation
Is Insmed undervalued compared to its fair value and its price relative to the market?
9.64x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate INSM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate INSM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: INSM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: INSM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INSM is overvalued based on its PB Ratio (9.6x) compared to the US Biotechs industry average (3.4x).
Next Steps
Future Growth
How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
56.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INSM's revenue (36.2% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: INSM's revenue (36.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSM is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Insmed performed over the past 5 years?
-20.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INSM is currently unprofitable.
Growing Profit Margin: INSM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: INSM has a negative Return on Equity (-59.68%), as it is currently unprofitable.
Next Steps
Financial Health
How is Insmed's financial position?
Financial Position Analysis
Short Term Liabilities: INSM's short term assets ($707.3M) exceed its short term liabilities ($78.8M).
Long Term Liabilities: INSM's short term assets ($707.3M) exceed its long term liabilities ($401.3M).
Debt to Equity History and Analysis
Debt Level: INSM's debt to equity ratio (85.4%) is considered high.
Reducing Debt: INSM's debt to equity ratio has increased from 6.5% to 85.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INSM has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 24.7% each year.
Next Steps
Dividend
What is Insmed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Will Lewis (51 yo)
8.08yrs
Tenure
US$7,175,094
Compensation
Mr. William H. Lewis, J.D., M.B.A., also known as Will, has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2 ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD7.18M) is about average for companies of similar size in the US market ($USD5.63M).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.08yrs | US$7.18m | 0.011% $ 440.4k | |
| Chief Operating Officer | 0.92yr | US$3.73m | 0.012% $ 469.4k | |
| Senior VP & Chief Accounting Officer | 1.58yrs | US$832.28k | 0.0034% $ 133.3k | |
| Chief Legal Officer & Corporate Secretary | 7.25yrs | US$2.71m | 0.037% $ 1.4m | |
| Chief People Strategy Officer | 7.75yrs | US$2.31m | 0.0083% $ 322.4k | |
| Chief Financial Officer | 0.75yr | no data | no data | |
| Chief Technology Officer | 9.83yrs | no data | no data | |
| Chief Compliance Officer | 2.75yrs | no data | 0.0049% $ 191.9k | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Senior VP & Head of United States | 0.92yr | no data | no data | |
| Chief Product Strategy Officer | 3.42yrs | US$1.69m | no data | |
| Head of Europe | 1.33yrs | no data | no data |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Management: INSM's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.08yrs | US$7.18m | 0.011% $ 440.4k | |
| Independent Director | 20.92yrs | US$272.50k | 0.28% $ 10.8m | |
| Independent Director | 7yrs | US$270.00k | 0.035% $ 1.4m | |
| Independent Director | 19.42yrs | US$262.50k | 0.24% $ 9.2m | |
| Independent Director | 8.17yrs | US$275.00k | 0.026% $ 998.9k | |
| Lead Independent Director | 1.92yrs | US$282.50k | 0.048% $ 1.9m | |
| Independent Director | 0.92yr | US$107.35k | no data | |
| Independent Director | 1.92yrs | US$255.00k | 0.0050% $ 197.0k | |
| Independent Director | 2.42yrs | US$257.50k | 0.016% $ 618.6k | |
| Director | 0.50yr | no data | no data |
2.2yrs
Average Tenure
62yo
Average Age
Experienced Board: INSM's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: INSM insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.
Top Shareholders
Company Information
Insmed Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Insmed Incorporated
- Ticker: INSM
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.908b
- Shares outstanding: 101.48m
- Website: https://www.insmed.com
Number of Employees
Location
- Insmed Incorporated
- 700 US Highway 202/206
- Bridgewater
- New Jersey
- 08807-1704
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| INSM | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2000 |
| IM8N | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2000 |
| IM8N | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Jun 2000 |
| 0JAV | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 2000 |
| INSM * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 2000 |
Biography
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/21 00:14 |
| End of Day Share Price | 2020/10/20 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.